| || |
PD Dr. rer. nat. habil. Markus Perbandt
University of Hamburg
Center for Ultrafast Imaging
Laboratory for Structural Biology of Infection and Inflammation
c/o DESY, Build. 22a
22607 Hamburg, Germany
Phone: 040 8998 - 4745
Fax: 040 8998 - 4747
Senior Reserach Associate at the Center for Ultrafast Imaging at the University of Hamburg (since 2013); Senior Research Associate at the Institute of Biochemistry and the Institute of Microbiology, Virology and Hygiene, University Medical Center Hamburg Eppendorf (2009-2012), Senior Research Associate at the Institute of Biochemistry, University of Lübeck (2007-2009); Research Associate at the Institute of Biochemistry, University of Hamburg (2001-2007); Postdoctoral Fellow at the Department of Biology, Massachusetts Institute of
Technology, Boston/USA (2000); Postdoctoral Fellow at the Center for Experimental Medicine, University Medical Center
Degrees and Education
>Habilitation and Venia Legendi in Biochemistry (2012, University of Hamburg), PhD (1999, Free University of Berlin), Study of Biochemistry and Molecular Biology (1990-1995, University of Hamburg)
Membership in Scientific Organizations
German Society for Biochemistry and Molecular Biology (GMB), German Society for Crystallography (DGK), American Society for Biochemistry and Molecular Biology (ASBMB), German Society for Parasitology (DGP).
Coordinator of the syndicate Hamburg-Lübeck for experimental research at the beamline X13 (EMBL/HASYLAB), Member of the HASYLAB User Committee
(2005-2008 and since 2001), Member of the scientific committee at DESY
(2006-2008); Educational Coordinator of the graduate school "Structure and Dynamics in Infection- SDI"
University of Münster (Prof. E. Liebau),
University Medical Center Hamburg-Eppendorf (Prof. M. Aepfelbacher), University of Veterinary Medicine Hannover (Prof. R. Goethe), Research Centre Borstel (Dr. U. Mamat), All India Institute of Medical Sciences (Prof. T.P. Singh), Bernhard-Nocht-Institute for Tropical Medicine (Prof. S. Günther), KIT (Prof. S. Bräse)
Structure-based drug and ligand design - Main focus eucaryotic parasits -
Structure based drug design originates from the central assumption that the
inhibitors or ligands bind to a molecular target. The prerequisite for a
strong binding is an extensive structural and chemical complementary between
the target and the ligand. The structure-based drug design is therefore the
search of a small molecule that fits perfectly into the binding pocket of
the target protein.
For the development of specific inhibitors or drugs against certain
illnesses or infections, it is of particular importance to characterize the
complex at high resolution. In order to reach this, the bio molecules are
crystallized and are examined by X-ray structural analysis. Based on these
results the structure-function relationship can be described very precisely.
Inhibitors or drugs must be very specific against the molecular targets to
avoid potential side effects with other proteins. This fact is of great
importance especially for the development of specific drugs against viruses,
bacteria or parasites, because finally the micro organism should be killed
and not the human being. Of course, the structure-based drug design finds
its application not only in medicine. Structural biology can also achieve
valuable services for the development of high affinity peptides against bio
molecules to modulate the binding affinity.
Complete directory of all publications (more then 80 reviewed publications, current H-index: 18)